However, the current overall efficacy of anti-PD-1/PD-L1 immunotherapies in solid tumors is less than 30% [6, 8], indicating that the PD-1/PD-L1 pathway is not the only one mechanism by which tumor immune escape occurs. Here, CD274 is linked to neoplasm.